AZD5213 + AZD5213 + AZD5213
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Cognitive Impairment
Conditions
Mild Cognitive Impairment, Mild Alzheimer's Disease
Trial Timeline
Apr 1, 2012 → Jan 1, 2013
NCT ID
NCT01548287About AZD5213 + AZD5213 + AZD5213
AZD5213 + AZD5213 + AZD5213 is a phase 2 stage product being developed by AstraZeneca for Mild Cognitive Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT01548287. Target conditions include Mild Cognitive Impairment, Mild Alzheimer's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01548287 | Phase 2 | Completed |
Competing Products
20 competing products in Mild Cognitive Impairment